Your cart is empty.
Männedorf, Switzerland, June 11, 2014 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that Ulrich Kanter has been appointed a member of the Management Board. As Head of the Development & Operations division, effective July 14, 2014, he will assume responsibility for development activities, production, supply chain management and materials purchasing at Tecan. Dr. Martin Brusdeilins, who has headed this division since November 2011, will retire at the end of September 2014 and step down from the Management Board. Until this time, he will continue to act as Chief Scientific Officer, a position that he holds in addition to being Head of the division. Tecan has initiated the search for a successor to take on this role.
Tecan CEO Dr. David Martyr commented: "I am very pleased that Ulrich Kanter will be strengthening the Tecan management team with his extensive experience in a variety of management positions in the diagnostic and life science industry. Tecan has great potential to considerably reduce product manufacturing costs through improvements in the supply chain, in materials purchasing and - in the medium term - throughout the development process. We have set this as a company-wide priority for 2014 and have launched a multiyear project. Ulrich Kanter brings with him a huge wealth of experience in implementing these types of projects and has a record of formidable successes.
I would like to thank Martin Brusdeilins personally and also on behalf of the entire management team and the Board of Directors for his valuable contribution to the development of Tecan. We wish him all the best for his retirement."
Ulrich Kanter worked in various areas and held diverse positions with increasing management responsibility at Roche Diagnostics from 2000. He was General Manager and Head of Research & Development in Graz, Austria, from 2007, with responsibility for the entire value chain of blood gas and electrolyte analysis systems for this Roche division. Prior to this, he managed the development of these systems as Senior Vice President Research & Development, and as Site Manager was responsible for management of the supply chain as well as all administrative matters at the Graz site.
From 1995 to 2000, Ulrich Kanter was Vice President Operations and Global Supply Chain Manager at AVL Medizintechnik, with responsibility for optimizing the supply chain and production processes of this product division. Following the acquisition of AVL Medizintechnik by Roche Diagnostics, as Senior Vice President Global Operations and Site Manager, he was responsible for the integration of the Graz site as well as all business activities in the Roche Group.
Between 1987 and 1995, Ulrich Kanter worked for companies in the Heraeus Group, initially in production management at W.C. Heraeus. From 1989, he held a management role in production planning and production management at Heraeus Instruments, a manufacturer of laboratory equipment including cell incubators (now part of Thermo Fisher Scientific) and lighting systems for operating theaters.
Ulrich Kanter is a graduate mechanical engineer (Berufsakademie Mannheim, Germany). He also completed a course of studies in business administration (Verwaltungs- und Wirtschaftsakademie at the J.W. Goethe University Frankfurt, Germany). He is 51 years old and a German citizen.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions
in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2013, Tecan generated sales of CHF 388 million (USD 419 million; EUR 316 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information: